Left for Dead Valeant Pharma (VRX) Is Up 30% In a Week
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Buy Valeant Pharmaceuticals (VRX) Ahead of Investor Day Catalyst - Guggenheim
November 24, 2015 8:02 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and $195 on Valeant Pharmaceuticals (NYSE: VRX) saying the stock has bottomed and multiple expansion will drive shares higher. Chen recommends buying ahead of the December 16, 2015 investor day catalyst.
"Concerns regarding high-priced drugs and specialty pharmacies have weighed on VRX shares since mid-September,... More
Philidor has dropped its litigation against R&O (VRX) - Evercore ISI's Raffat
November 23, 2015 10:33 AM ESTPhilidor has dropped its litigation against R&O, letting Valeant Pharma (NYSE: VRX) continue with similar litigation - Evercore ISI's Umer Raffat said.
... MoreValeant Pharma (VRX) Products are Selling Ex-Philidor - Evercore ISI's Raffat
November 20, 2015 3:29 PM ESTEvercore ISI analyst Umer Raffat notes the uptick in Valeant Pharma (NYSE: VRX) IMS script data could be coming as products are being rolled over from Philidor (which is not tracked by IMS) to more traditional specialty pharmacies (which are tracked by... More
Valeant Pharma (VRX) Adds to Strong Gains; Sets Sights on $90
November 20, 2015 1:10 PM ESTShort seller target Valeant Pharma (NYSE: VRX) is seeing notably strength again today on the back of yesterday's 16% move up. Shares last traded up 5.6% to $88.73.
Yesterday, Citi endorsed the credit with an Overweight rating and today Mizuho reiterated it as a top pick, saying "the stock appears to have bottomed."
... MoreValeant Pharmaceuticals (VRX) Reiterated Top Pick at Mizuho Securities; PT to $111
November 20, 2015 6:36 AM ESTMizuho Securities analyst Irina Koffler reiterated Valeant Pharmaceuticals (NYSE: VRX) as their Top Pick while maintaining an Outperform rating and lowering thier price target to $111.00 (from $155.00).
The analyst highlighted:
The stock appears to have bottomed, in our view: We are by no means ignoring the risks tied to this stock. We worry about expansion of existing investigations, congressional probes of Philidor, and potential changes to senior management. All that said, we believe that the risk/reward in VRX is still favorable given business fundamentals. We are primarily... MoreValeant Pharma (VRX) Surges as Co's Debt Gets Endorsed
November 19, 2015 10:05 AM ESTBeaten down Valeant Pharma (NYSE: VRX) is up 9% early to $79, benefiting from today's Overweight rating on the company's debt at Citi.
The firm cited product diversification and strong FCF generation.
... MoreCiti Credit Research Sees Opportunity in Valeant (VRX), Initiates With Overweight Rating (MNK) (ENDP)
November 19, 2015 9:28 AM ESTCiti Credit Research initiated coverage on Valeant Pharma (NYSE: VRX) with an Overweight rating. Analysts noted its global footprint, product diversification and strong FCF generation. Peers Mallinckrodt (NYSE: MNK) and Endo (NASDAQ: ENDP) were... More
